Ceisteanna ó na Comhaltaí Eile - Other Members’ Questions Dail Éireann — 2026-04-23 ============================================================ Simon Harris (FG), Wicklow I thank the Deputy very much for raising this important matter. I acknowledge that, as he rightly reminded the House, this is not the first time he has raised this issue here, and directly with the Minister for Health as well. There has been a welcome and renewed policy focus in this House and from the Government on the importance of HRT treatment and accessibility to the free HRT programme. I thank my colleague the Minister, Deputy Carroll MacNeill, for the work she has done in getting this programme up and running that is helping many women across the country. I say that before getting to the Deputy's specific point. He raised the medicine, Veoza. My understanding is that the HSE received an application for pricing and reimbursement of Veoza on 9 February 2024 from the pharma company. It is for the treatment of moderate to severe vasomotor symptoms associated with menopause. On foot of a rapid review by the NCPE, the body that reviews medicines on behalf of the State, the HSE commissioned a full health technology assessment, HTA, on 8 April 2024, as per agreed processes. Often the State gets blamed for being slow but it is important to say that 16 months passed before the company submitted the completed HTA dossier. I say that because people often ask why the Government does not move quicker. Sixteen months passed from when the NCPE said it was going to carry out the HTA to when the company submitted the dossier. That fact should be made known as well. When the NCPE did receive the full dossier it carried out its work and, as the Deputy says, it issued a report. I thank the NCPE for the work it is doing. The factual position now is that the HSE will contact the company with a view to commencing commercial negotiations. I want to be very careful not to interfere with that. The Deputy is not doing that either. We need to allow the HSE to do its job in terms of carrying out that commercial negotiation. We are now spending €4 billion a year on drugs, which is good, as we need to do so. That is more than the budget of many stand-alone Departments. The budget for the Department of justice is probably around €6 billion. We are spending €4 billion on our drugs budget, so we have to allow the HSE do its commercial negotiation and get the best value for the taxpayer because obviously if it does not, it will affect the ability to purchase other drugs as well. I recognise the importance of timely access to new medicines. I take the point the Deputy made about certain women who cannot access other treatments. I take very seriously the point he made about cancer patients and also cancer survivors. In terms of modifying the free HRT programme to include non-hormonal treatment - I will not comment on the specific drug given the negotiations, as I do not want to cut across that - but any of the more broad matters concerning the programme and the likes are a matter for budget time. I am very happy to engage with the Deputy on that then. The main thing now is for the HSE to contact the company and get into commercial negotiations. --- Source: Houses of the Oireachtas. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The Official Report is revised after first publication; the fetch timestamp below identifies the version quoted. Record URI: https://data.oireachtas.ie/akn/ie/debateRecord/dail/2026-04-23/debate/main Retrieved: 2026-08-27T06:54:48+00:00 Sitting date: 2026-04-23